Acute myelogenous leukemia | India| PDF | PPT| Case Reports | Symptoms | Treatment

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Acute Myelogenous Leukemia

  • Acute myelogenous leukemia

    Acute myelogenous leukaemia (AML) is a malignant disease of the bone marrow in which hematopoietic precursors are arrested in an early stage of development. A comprehensive search to identify studies addressing outcome of childhood AML from India was carried out. International Society of Paediatric Oncology annual meeting abstracts were searched to identify unpublished data. Clinicodemographic and outcome data were extracted from these abstracts. Survival outcomes are modest (23% to 53.8%) except for AML M3 (over 80%), with high early-death rates, relapse, along with abandonment. Few series have identified prognostic parameters and disease burden at diagnosis, and used cytogenetics (for risk stratification) or bone marrow transplant (BMT).

  • Acute myelogenous leukemia

    Symptoms: The hidden pathophysiology in AML comprises of a maturational capture of bone marrow cells in the most punctual phases of improvement. The system of this capture is under concentrate, yet as a rule, it includes the initiation of irregular qualities through chromosomal translocations and other hereditary variations from the norm.Patients with AML ought to be told to call their medicinal services suppliers quickly on the off chance that they are febrile or have indications of dying. For patient training assets, see the Blood and Lymphatic System Center and the Skin, Hair, and Nails Center, and in addition Leukemia and Bruises.

  • Acute myelogenous leukemia

    Therapeutic aspects: Current standard chemotherapy regimens cure just a minority of patients with AML. Therefore, all patients ought to be assessed for section into all around outlined clinical trials. On the off chance that a clinical trial is not accessible, the patient can be treated with standard treatment. For combination chemotherapy or for the administration of harmful impacts of chemotherapy, readmission is required.


Speaker PPTs

High Impact List of Articles

Conference Proceedings